Editorial
New Drug Development and the Health Care Crisis

Scientific Contributions
Angiotensin II Receptor Subtype mRNAs
Distribution and Regulation of AT$_{1A}$ and AT$_{1B}$ Receptor mRNAs
Ouabain in Human Plasma
Autonomic Nervous System and Hypertension
Prehypertensive DOCA Rats
Chronic Aldosterone Depresses Baroreceptor Reflex Function
Aerobic Fitness, Blood Pressure, and Autonomic Responses
Hemodynamic Predictors of Hypertension
Angiotensinogen in Essential Hypertension
Molecular Cloning of $\alpha_5$
Production and Clearance of Adrenomedullin
Dyslipoproteinemia in Borderline Hypertension
SHR and Spinal Nicotinic Receptors
Heat-Shock Proteins in Hypertension
Antihypertensive Effects of Vanadyl Sulfate
Effects of Felodipine During Metoclopramide

Letters to the Editor
Putative Endogenous Digitalis-like Factors
International Society for Heart Research North American Section
Annual Sessions
Cellular and Molecular Regulation of Cardiovascular Structure and Formation

American Heart Association
Fighting Heart Disease and Stroke

May 21-25, 1995
Perdido Beach Resort
Orange Beach, Alabama

Multiple Symposia on 1) Cardiovascular Development and Growth 2) New Frontiers of Cardiovascular Disease 3) Myocardial Hypertrophy and Failure 4) Ischemic Myocardial Injury and 5) Scientific Conference on the Pathophysiology of Tachycardia Induced Dilated Cardiomyopathy. This portion of the program is partially sponsored by the American Heart Association Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Circulation.

Abstract Deadline: January 31, 1995

Meeting information, abstract forms and information on Young Investigator Awards may be obtained through:
Sanford P. Bishop, D.V.M., Ph.D.
ISHR Annual Meeting Information
University of Alabama at Birmingham
Department of Pathology
1670 University Blvd. VH G038
Birmingham, AL 35294-0019
Tel. 205-934-4613 Fax 205-934-1775
The American Heart Association invites you to fax your journal order directly to us. Your personal subscription will be processed quickly and delivery will be dependable. Institutional rates are available on request.

Journal Subscription Fax-Form

Please check the boxes on the right for the journals you wish to receive. Overseas issues are sent by air-expedited service. US copies are sent by the United States Postal Service.

This form is designed to be telefaxed. If you prefer to mail your order, simply complete the fax-form and mail it to:

American Heart Association
Scientific Publishing
7272 Greenville Avenue
Dallas, TX 75231-4596
USA

or

Telephone your order by calling:
(214) 706-1310

Advance payment is required. Charge your subscription to a credit card or send a check directly to the AHA.

Journals No. of Issues International Rate US Rate

- Arteriosclerosis and Thrombosis 12 US $200 $146
- Circulation 12 US $242 $124
- Circulation Research 12 US $256 $172
- Hypertension 12 US $188 $124
- Stroke 12 US $184 $124
- Cardiovascular Nursing 6 US $15 $6
- Currents in Emergency Cardiac Care 4 US $16 $12

*Beginning January 1995, CIRCULATION will be published twice monthly

Amount $___________

Name________________________________________________________ Degree______________________
Address______________________________________________________
______________________________________________________________________________
Country________________________________________________________
Telephone__________________________Fax__________________________
Start my subscription with the ____________ issue.
Date of Birth________________________Gender________________________Race________________________
My specialty is________________________________________________________

☐ Check enclosed Make checks payable to the American Heart Association in US dollars drawn on a US bank.

☐ Visa ☐ MasterCard ☐ American Express

Card number________________________Expiration date________________________
Signature__________________________

This offer expires January 31, 1995

4JLL01/2
In hypertension or angina...

"When you're taking something for the rest of your life, you really want to feel comfortable with it."

Control That's Easy to Live With

Once-Daily NORVASC®

(amlodipine besylate)
In hypertension or angina...
Control That's Easy to Live With

HIGH RATE OF SUCCESS IN AN NIH-SPONSORED STUDY

83% of hypertensive patients—the highest percentage—remained on initial therapy with NORVASC® (amlodipine besylate) after 4 years; nearly all patients were on the 5-mg starting dose.

LOW RATE OF DISCONTINUATION

ONLY 1.5% of patients in placebo-controlled studies (n=1730) discontinued therapy due to adverse effects.

PROVEN SAFETY

No negative inotropic effects at clinical doses in hemodynamic studies.*
No clinically significant effect on cardiac conduction or heart rate.

*NORVASC reg; hemodynamic findings, however, have been observed with agents possessing significant negative inotropic effects.

Once-Daily NORVASC®
(amlodipine besylate)

5-mg and 10-mg tablets

EFFICACY AND SAFETY THAT'S EASY TO LIVE WITH

Please see brief summary of prescribing information on last page.
In hypertension or angina, convenient once-daily dosing

- The usual starting dose is 5 mg in hypertension or angina
  - In hypertension, small, frail, or elderly individuals, or patients with hepatic insufficiency may be started on 2.5 mg once daily
- Titration can proceed to 10 mg
  - Most angina patients will require 10 mg
- Can be taken with or without food
- The most common side effects are headache and edema

O.N.V.A.S.C.
(amlodipine besylate)

Revised July 1993

More detailed professional information available on request.

References
To Get Ahead
You've Got To Pay Your Dues.

More than 26,000 medical researchers and physicians are members of one or more of the AHA's 14 scientific councils. By joining a scientific council, you can broaden your knowledge and increase your expertise, widen your network of colleagues...and make a real impact in your chosen field.

In addition, members of the AHA's scientific councils are eligible for these benefits:

- A reduced registration fee for the annual AHA Scientific Sessions and other council-sponsored meetings.
- A 20 percent discount on subscriptions to AHA scientific journals.
- A newsletter with updates on council activities and issues of interest to members.

The AHA's 14 scientific councils are:

<table>
<thead>
<tr>
<th>Council</th>
<th>Annual Dues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arteriosclerosis</td>
<td>$25</td>
</tr>
<tr>
<td>Basic Science</td>
<td>25</td>
</tr>
<tr>
<td>Cardiopulmonary and Critical Care</td>
<td>25</td>
</tr>
<tr>
<td>Cardiovascular Disease in the Young</td>
<td>25</td>
</tr>
<tr>
<td>Cardiovascular Nursing</td>
<td>25</td>
</tr>
<tr>
<td>Cardiovascular Radiology</td>
<td>25</td>
</tr>
<tr>
<td>Cardio-Thoracic and Vascular Surgery</td>
<td>35</td>
</tr>
<tr>
<td>Circulation</td>
<td>20</td>
</tr>
<tr>
<td>Clinical Cardiology</td>
<td>30</td>
</tr>
<tr>
<td>Epidemiology and Prevention</td>
<td>25</td>
</tr>
<tr>
<td>High Blood Pressure Research* (U.S.)</td>
<td>104 (Outside U.S.) 139</td>
</tr>
<tr>
<td>Kidney in Cardiovascular Disease</td>
<td>30</td>
</tr>
<tr>
<td>Stroke</td>
<td>35</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>25</td>
</tr>
</tbody>
</table>

* includes a subscription to Hypertension

Name ______________________________ Specialty __________ Year of Birth ________
Address ______________________________ State ________ Country __________
City ________________________________ Phone __________________ Fax __________

☐ Check/money order enclosed (U.S. dollars drawn on a U.S. bank)
☐ MasterCard ☐ Visa Exp. Date __________________

Credit Card # _______________________
Signature as it appears on the card ___________________

Return to: American Heart Association
Scientific Publishing
7272 Greenville Avenue
Dallas, Texas 75231-4596
or Fax (214) 691-6342

2048 4CNL09
Public Access Defibrillation: A New Strategy To Prevent Sudden Death

An American Heart Association Conference Focused on the Interface Between Medicine, Engineering, Public Health and Industry

Topics:
- Integration of Automatic External Defibrillation Into the Community
- Current and Developing Automatic External Defibrillator Technology
- Cost Effectiveness of Early Defibrillation
- Return on Investment for Successful New Products
- Moving AEDs Into the Domain of Consumer Electronics
- Behavioral Aspects of Early Defibrillation
- Integration of Defibrillation Into Modern Communications Technology
- Public Policy and Legal Considerations for Next Generation of Devices
- Integration of Automatic External Defibrillation Into Healthcare of the Future

Contact: Patricia Bowser
American Heart Association
7272 Greenville Avenue
Dallas, TX 75231-4596
Telephone (415) 637-8500

II International Symposium on DRUGS AFFECTING LIPID METABOLISM
Houston, Texas, USA
November 7-10, 1995

CHAIRMEN: A.M. Gotto, Jr. (USA) and R. Paoletti (Italy)

PURPOSE OF THE SYMPOSIUM
The Symposium will focus on VASCULAR PROTECTION AND PATHOBIOLOGY, including lipid metabolism and signaling systems; RISK FACTORS AND EPIDEMIOLOGY, including fibrinogen, tissue factor, factor VII; and NEW HORIZONS IN THE MOLECULAR BASIS OF ATHEROSCLEROSIS, including gene therapy. The most recent discoveries and future trends in research and treatment will be discussed by leading scientists in the field.

ORGANIZING SECRETARIAT
XII DALM
Giovanni Lorenzini Medical Foundation
6550 Fannin, Suite 1423
Houston, TX 77030 USA
Tel: (713) 797-0401
Fax: (713) 796-8853

for Europe:
Giovanni Lorenzini Fondazione
Via Appiani 7
20121 Milan, Italy
Tel: (02) 29.00.62.67
Fax: (02) 29.00.70.18

Free On-Line Document Search...
Discount on Document Delivery

Announcing Access to UnCover
Document search and delivery for readers of Hypertension

You can now access free of charge the UnCover on-line database of the complete table of contents information from over 15,000 journals. In addition, you can order delivery of full text of articles at a discount of $2.00 per article off the regular document delivery price—a discount normally available only to UnCover subscribers who pay an annual password fee.

With Access to UnCover, you can search for articles on particular topics, by particular authors, or from particular journals. You can then order on-line the full text of articles for delivery by fax within 24 hours. Document delivery fees will be billed to your credit card.

Access to UnCover is available now over the Internet. Simply Telnet to the Access to UnCover Address: allen.carl.org, and then at the prompt, enter the Password: DELIVER

Access to UnCover makes it easy to find the articles you need.
THE VALUE OF EXPERIENCE

BENEFIT FROM THE EXPERIENCE

• Proven 24-hour control in hypertension
• Proven 24-hour control in angina
• Over 1.8 billion patient therapy days reported*

EXPERIENCE THE BENEFITS

• Well tolerated
• Effective in a wide range of patient types1-5
• Consistent 24-hour plasma levels6
• No clinically significant effect on heart rate2,3

once-a-day PROCARDIA XL®
(nifedipine) extended release
Tablets 30mg, 60mg and 90mg GITS

*Methodology on file at Pratt Pharmaceuticals, derived from NPA Plus™,
IMS America, Ltd., 1993.

Please see brief summary of prescribing information on adjacent page.

**CONVIVENT DOING**

- Easy to titrate
- Convenient AM or PM dosing
- Can be taken with or without food

**WELL-TOLERATED THERAPY**

Side effects include peripheral edema, which is not associated with fluid retention, and headache.

In controlled clinical trials of 776 patients with PROCARDIA XL, edema resulted in discontinuation of therapy in 2.6% of patients.

**Cardiovascular, Congenital Heart Disease, Pregnancy**

PROCARDIA XL is contraindicated in patients with overt or uncontrolled congestive heart failure, severe hypotension, or second or third degree atrioventricular block. Use in patients with severe hepatic impairment is not recommended.

**Dizziness**

Dizziness occurs in over 10% of patients. In over 1000 patients from both controlled and open trials with PROCARDIA XL Extended Release Tablets in hypertension and angina were included in the evaluation of adverse experiences. All side effects reported during PROCARDIA XL Extended Release Tablet therapy were independent of their usual relation to medication. The most common side effect reported during PROCARDIA XL therapy was edema, which was dose-related and ranged from 1 to 6% of all patients. Very rare adverse experiences reported during long-term therapy included edema, weight gain, and fluid retention. No specific treatment other than discontinuation of PROCARDIA XL Extended Release Tablets is necessary in most cases. Some patients have continued to tolerate the drug despite marked edema.

**Laboratory Tests:**

Red, white, and platelet counts, and various coagulation tests are normal. Approximately 1% of patients have had isolated increases in alkaline phosphatase, SGOT, and SGPT. In one patient, a small increase in direct bilirubin was noted without any clinical signs or symptoms.

**Other**

The incidence of adverse experiences remained unchanged at all dose levels, and the incidence of adverse experiences at the maximum human dose was comparable to the incidence observed at lower doses. The incidence of adverse experiences was similar to that observed in patients receiving placebo. Adverse experiences were generally transient and did not require discontinuation of therapy.

**ADVERSE EXPERIENCES:**

Over 1000 patients from both controlled and open trials with PROCARDIA XL Extended Release Tablets in hypertension and angina were included in the evaluation of adverse experiences. All side effects reported during PROCARDIA XL Extended Release Tablet therapy were independent of their usual relation to medication. The most common side effect reported during PROCARDIA XL therapy was edema, which was dose-related and ranged from 1 to 6% of all patients. Very rare adverse experiences reported during long-term therapy included edema, weight gain, and fluid retention. No specific treatment other than discontinuation of PROCARDIA XL Extended Release Tablets is necessary in most cases. Some patients have continued to tolerate the drug despite marked edema.